Lead Optimization of a Pyrazole Sulfonamide Series of Trypanosoma brucei N -Myristoyltransferase Inhibitors: Identification and Evaluation of CNS Penetrant Compounds as Potential Treatments for Stage 2 Human African Trypanosomiasis

Citations Over TimeTop 10% of 2014 papers

Abstract

Trypanosoma brucei N-myristoyltransferase (TbNMT) is an attractive therapeutic target for the treatment of human African trypanosomiasis (HAT). From previous studies, we identified pyrazole sulfonamide, DDD85646 (1), a potent inhibitor of TbNMT. Although this compound represents an excellent lead, poor central nervous system (CNS) exposure restricts its use to the hemolymphatic form (stage 1) of the disease. With a clear clinical need for new drug treatments for HAT that address both the hemolymphatic and CNS stages of the disease, a chemistry campaign was initiated to address the shortfalls of this series. This paper describes modifications to the pyrazole sulfonamides which markedly improved blood-brain barrier permeability, achieved by reducing polar surface area and capping the sulfonamide. Moreover, replacing the core aromatic with a flexible linker significantly improved selectivity. This led to the discovery of DDD100097 (40) which demonstrated partial efficacy in a stage 2 (CNS) mouse model of HAT.

Related Papers

• → Solid phase synthesis of ‘head-to-tail’ cyclic peptides using a sulfonamide ‘safety-catch’ linker: the cleavage by cyclization approach(1999)68 cited
• → Antiproliferative Activity of New Pyrazole-4-sulfonamide Derivatives: Synthesis and Biological Evaluation(2023)13 cited
• → Versatile solid-phase synthesis of secondary amines from alcohols. Development of an N-Boc-(o-nitrobenzene)sulfonamide linker(2003)13 cited
• → Enzymatic formation of prostaglandin D2, E2, and F2α in the parasitic protozoan Trypanosoma brucei(2002)3 cited
• → Novel forms of oral melarsoprol cure CNS stage Trypanosoma brucei brucei infection in a murine model of human African trypanosomiasis(2008)